We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Managing Neovascular Age-Related Macular Degeneration Is More Research Needed to Improve Real-world Practice?

Gianni Virgili, MD1; Mariacristina Parravano, MD2; Christine Schmucker, PhD3
[+] Author Affiliations
1Department of Translational Surgery and Medicine, Eye Clinic, University of Florence, Florence, Italy
2Department of Ophthalmology, Fondazione G. B. Bietti per lo Studio e La Ricerca in Oftalmolologia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
3Cochrane Germany, University Medical Center Freiburg, Freiburg
JAMA Ophthalmol. 2016;134(5):553-554. doi:10.1001/jamaophthalmol.2016.0332.
Text Size: A A A
Published online


Population-based data from registries of blind people confirm that antiangiogenic therapy has had a substantial role in reducing the burden of vision loss in patients with neovascular age-related macular degeneration (AMD).1 These data are also affirmed by results obtained from randomized clinical trials (RCTs). However, in contrast to RCTs, patient-relevant outcomes from observational studies indicate that the initial gain in visual acuity (VA) is not maintained after a few years in these patient populations. A comprehensive analysis2 of real-world ranibizumab study data confirmed that patient-relevant outcomes are considerably poorer in observational studies than those reported in RCTs using fixed or as-needed (PRN) regimens, meaning that patients with neovascular AMD are often undertreated and undermonitored in many settings.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections